SCHEMBL410187

SCHEMBL410187

COC(=O)c1ccc(OCC(O)Cn2c3ccccc3c3ccccc32)cc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.69
LMNA P02545 8/20 0.69
L3MBTL1 Q9Y468 1/20 0.69
MEN1 O00255 3/20 0.69
KMT2A Q03164 3/20 0.69
RECQL P46063 2/20 0.69
KDM4E B2RXH2 2/20 0.69
CYP1A2 P05177 2/20 0.69
CYP3A4 P08684 2/20 0.69
CYP2D6 P10635 2/20 0.69
CYP2C9 P11712 2/20 0.69
CYP2C19 P33261 2/20 0.69
NPSR1 Q6W5P4 1/20 0.69
TP53 P04637 1/20 0.64
THRB P10828 1/20 0.64
ALDH1A1 P00352 3/20 0.56
HPGD P15428 2/20 0.55
GAA P10253 2/20 0.55
HTT P42858 1/20 0.55
POLB P06746 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18930636 0.90 LMNA (0.67) MAPTLMNAL3MBTL1MEN1KMT2A
SCHEMBL19547484 0.86 MAPT (0.77) MAPTLMNAL3MBTL1MEN1KMT2A
SCHEMBL411339 0.84 LMNA (0.80) MAPTLMNAL3MBTL1MEN1KMT2A
SCHEMBL410820 0.82 LMNA (1.00) MAPTLMNAL3MBTL1MEN1KMT2A
SCHEMBL411822 0.81 LMNA (1.00) MAPTLMNAL3MBTL1MEN1KMT2A
SCHEMBL14690064 0.80 MAPT (0.54) MAPTLMNAL3MBTL1MEN1KMT2A
SCHEMBL14689242 0.80 LMNA (0.63) MAPTLMNAL3MBTL1MEN1KMT2A
SCHEMBL18925969 0.80 MAPT (0.70) MAPTLMNAL3MBTL1MEN1KMT2A
SCHEMBL19559314 0.79 MAPT (0.61) MAPTLMNAL3MBTL1KMT2AKDM4E
SCHEMBL19559285 0.78 LMNA (0.69) MAPTLMNAL3MBTL1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180318255-A1 Pro-Neurogenic Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2018-11-08 US claimed
EP-2590647-B1 PRO-NEUROGENIC COMPOUNDS UNIV TEXAS (US) 2017-11-08 EP claimed
US-20170157092-A1 Anti-depression Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2017-06-08 US claimed
US-20160362372-A1 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2016-12-15 US claimed
US-20160206596-A1 Anti-depression Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2016-07-21 US claimed
US-20160206594-A1 Pro-Neurogenic Compounds NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-07-21 US claimed
US-20150290195-A1 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2015-10-15 US claimed
EP-2925129-A1 PRO-NEUROGENIC COMPOUNDS Board of Regents of the University of Texas System (US) 2015-10-07 EP claimed
US-20150057301-A1 Pro-Neurogenic Compounds NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-02-26 US claimed
US-20140343018-A1 Anti-depression Compounds NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2014-11-20 US claimed
US-20130184301-A1 Methods of Treating Post-Traumatic Stress Disorder Using Pro-Neurogenic Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2013-07-18 US claimed
EP-2590647-A2 PRO-NEUROGENIC COMPOUNDS Board of Regents of the University of Texas System (US) 2013-05-15 EP claimed
US-20130040977-A1 Pro-Neurogenic Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2013-02-14 US claimed
US-20120022096-A1 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-01-26 US claimed
WO-2012006419-A2 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-01-12 WO claimed
EP-2385829-A1 PRO-NEUROGENIC COMPOUNDS Board of Regents of the University of Texas System (US) 2011-11-16 EP claimed
US-8039041-B2 Electroluminescent devices with electrode protection CAMBRIDGE DISPLAY TECHNOLOGY, LTD. (GB) 2011-10-18 US claimed
US-20110015217-A1 Pro-Neurogenic Compounds BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2011-01-20 US claimed
US-20110003836-A1 Pro-Neurogenic Compounds BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2011-01-06 US claimed
WO-2010081115-A1 PRO-NEUROGENIC COMPOUNDS UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER (US) 2010-07-15 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130184301-A1 Methods of Treating Post-Traumatic Stress Disorder Using Pro-Neurogenic Compounds BDNF, GAP43, DCX MAPT 578/4885LMNA 993/4885L3MBTL1 1989/4885
US-20120022096-A1 PRO-NEUROGENIC COMPOUNDS BDNF, GAP43, DCX MAPT 136/4885LMNA 174/4885L3MBTL1 556/4885
US-20160206594-A1 Pro-Neurogenic Compounds DCX, GAP43, BDNF MAPT 559/4885LMNA 654/4885L3MBTL1 1527/4885
US-20150057301-A1 Pro-Neurogenic Compounds DCX, GAP43, BDNF MAPT 620/4885LMNA 521/4885L3MBTL1 1684/4885
US-20180318255-A1 Pro-Neurogenic Compounds BDNF, GAP43, DCX MAPT 136/4885LMNA 174/4885L3MBTL1 556/4885
US-20110015217-A1 Pro-Neurogenic Compounds DCX, GAP43, BDNF MAPT 559/4885LMNA 654/4885L3MBTL1 1527/4885
US-20150290195-A1 PRO-NEUROGENIC COMPOUNDS DCX, GAP43, BDNF MAPT 559/4885LMNA 654/4885L3MBTL1 1527/4885
US-20140343018-A1 Anti-depression Compounds BDNF, DCX, GAP43 MAPT 142/4885LMNA 523/4885L3MBTL1 364/4885
US-20130040977-A1 Pro-Neurogenic Compounds BDNF, GAP43, DCX MAPT 136/4885LMNA 174/4885L3MBTL1 556/4885
US-20110003836-A1 Pro-Neurogenic Compounds DCX, GAP43, BDNF MAPT 571/4885LMNA 628/4885L3MBTL1 1610/4885
US-20160362372-A1 PRO-NEUROGENIC COMPOUNDS DCX, GAP43, BDNF MAPT 559/4885LMNA 654/4885L3MBTL1 1527/4885
US-20160206596-A1 Anti-depression Compounds BDNF, DCX, GAP43 MAPT 142/4885LMNA 523/4885L3MBTL1 364/4885
US-20170157092-A1 Anti-depression Compounds BDNF, DCX, GAP43 MAPT 142/4885LMNA 523/4885L3MBTL1 364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.